An interventional study of Additional visualisation of surgical assistance during surgery in Rectum Cancer, sponsored by Technische Universität Dresden. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Technische Universität Dresden · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Rectal Neoplasms with a site in Germany — 17 open to participants now, 27 under way, 4 of them phase 3. Rectal Neoplasms · Germany.
Among the 78 studies in Rectal Neoplasms with a site in Germany, this one is the 59th largest by planned enrollment of the 62 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 with no phase, reaches primary completion later than 14 of the 26 other live ones, and was the 64th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →17 of the 78 studies in Rectal Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
University Hospital Tuebingen · Sites in Germany
Ages 18+
Gruppo Oncologico del Nord-Ovest · Sites in Germany, France, Italy and 1 more country
Ages 18+
Delcath Systems Inc. · Sites in Germany, United States, Czechia and 6 more countries
Ages 18+
brenner baruch · Sites in Germany, Israel
Ages 18+
Merck Sharp & Dohme LLC · Sites in Germany, United States, Argentina and 26 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 24 · Phase 3 19 · Phase 4 1
First in 1991; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 124 across the 62 interventional studies, 596 across the 14 observational. Of the 41 that completed or were terminated, 4 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 78 have an industry lead sponsor. The 10 most frequent:
Technische Universität Dresden is the lead sponsor of 247 studies on the registry; 46 are open to participants now.
Technische Universität Dresden has 1 study filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
5 of the studies in Rectal Neoplasms with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
| NCT04184973Colospan Ltd.Efficacy and Safety of the CG-100 Intraluminal Bypass Device | 2026-12-31 |
| NCT05652361Technische Universität DresdenMachine Learning-based Surgical Guidance System for Robot-assisted Rectal Surgery | 2027-01 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
| NCT07407465Gruppo Oncologico del Nord-OvestUpfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | 2027-10-20 |
Add all 5 to your calendar (.ics) → With an account.
Among the 78 studies in Rectal Neoplasms with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to evaluate the technical feasibility and applicability of a surgical assistance system based on image recognition algorithms in a first-in-human pilot study. In addition, this study will provide preliminary data on the oncological outcome of the assistance system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Additional visualisation of surgical assistance during surgery
Robot-assisted anterior rectal resection using daVinci® system as CE-marked gold standard with additional visualization of surgical assistance functions based on machine learning techniques
Incidence of discrepancies between the surgeon's preparation and the prediction of the CoBot system
System discrepancy score quantifying major misspecifications of the CoBot system in comparison to the surgeon's action
Time frame: 72 hours after Surgery
Operating time [min]
Time from skin incision until placement of last skin staple/suture
Time frame: During Surgery
Duration of postoperative hospital stay [days]
Postoperative day 1 until day of discharge
Time frame: At day of discharge, assessed up to 5 days
Duration of postoperative intermediate/intensive care unit stay [days]
Postoperative day 1 until day of discharge
Time frame: At day of discharge, assessed up to 5 days
Frequency of peri-operative morbidity after resection
Frequency of peri-operative complications after surgery until Day of Discharge
Time frame: At day of discharge, assessed of up to 5 days
Kind of peri-operative morbidity after resection
Kind of peri-operative complications after surgery until day of discharge
Time frame: At day of discharge, assessed of up to 5 days
Assessment of the circumferential resection margin (CRM)
Rate of R0 resections
Time frame: At day of discharge, assessed up to 5 days
Number of resected lymphnodes
Number of lymphnodes resected during surgery
Time frame: During surgery
Assessment of pelvic function before and after rectal resection
Rectal function will be assessed preoperatively and 12-15 months postoperatively using the standard LARS score questionnaire, resulting in a score between 0 and 42. Higher scores mean a worse outcome (worse pelvic function).
Time frame: 15 months
Rectal sphincter function before and after rectal resection
Sphincter function will be assessed by manometry preoperatively and 12 - 15 months postoperatively
Time frame: 15 months
Assessment of the difficulty of the preparation
Surgeon questionnaire, the questionnaire qualitatively assesses nine items, each item scoring from "not at all" to "very much", evaluated individually
Time frame: 48 hours after surgery
Assessment of usability of guidance system
One-time final survey of all participating surgeons, the questionnaire qualitatively assesses nine items, each item scoring from "not at all" to "very much", evaluated individually
Time frame: Through study completion, an average of 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.
Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 11 months is below that.
Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Technische Universität Dresden →